Oncology & Immunosuppressant
Pharmaceutical Manufacturing

Safe and Operationally Efficient Oncology & Immunosuppressant
Drug Manufacturing Facility Located in North America.

Opened in 2023 and located at PiSA’s Tlajomulco Campus, 30 Minutes south of Guadalajara, this World Class Facility Provides Leading Pharmaceutical Companies with Exceptional Contract Manufacturing Capabilities.

High-Volume Oral Dose
& Injectable Manufacturing

PiSA’s Oncological and Immunosuppressant Manufacturing facility can currently produce 10 million doses of injectables and 500 million doses of oral solids annually. PiSA’s Immunosuppressant facility has the capacity to produce 200 million capsules, tablets, and vials.

World Class Plant & Equipment

PiSA has invested in state-of-the-art, cutting-edge equipment to ensure quality and reliability for high volume manufacturing. These include, automated mixers, grinders, tablet and capsule formulation, blister pack systems, independent HVAC and water purification systems, automated cleaning systems, magnetic stirring, vaporized hydrogen peroxide generators and two 200 sq. ft. Lyophilization systems.

Safety

Containment is the key consideration when manufacturing these pharmaceuticals for safety and prevent cross contamination. The entire facility operates at Occupational Exposure Band 5 to ensure operator health and safety. All processes are hermitically sealed, using sampling isolators and active weighing and integrate hermetically sealed bins. Automated Clean-in-Place and Wash-in-Place Systems ensure zero cross contamination.